Impact of Scleroderma‐Associated Autoantibodies on Clinical Outcome Assessments: Post Hoc Analysis From a Randomised, Double‐blind, Placebo‐controlled, Phase 3 Trial of Tocilizumab in Scleroderma
Objective Scleroderma‐associated autoantibodies (SSc‐Abs) are specific in participants (pts) with systemic sclerosis and are associated with organ involvement. Our objective was to assess the influence of baseline SSc‐Abs on the trajectories of the clinical outcome assessments (COAs) in a phase III...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | Inglês |
| 出版: |
Wiley
2025-01-01
|
| 丛编: | ACR Open Rheumatology |
| 在线阅读: | https://doi.org/10.1002/acr2.11782 |
| 标签: |
没有标签, 成为第一个标记此记录!
|